Pay in 4 interest-free payments of $5.86 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
Benefits for certain uses Faster absorption: The injectable route bypasses some of the barriers of nasal or oral delivery
Br J Hosp Med Lond Engl
The NDA is based on results from REDEFINE 1, a 68-week, phase 3, randomised, double-blind, placebo-and active-controlled trial that evaluated the efficacy and safety of once-weekly, CagriSema compared to semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo, all as an adjunct to lifestyle intervention in 3,417 adults with obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2) with one or more obesity-related complications and without diabetes, and REDEFINE 2, a double-blind, randomised, placebo-controlled, 68-week, phase 3 trial that evaluated the efficacy and safety of once-weekly CagriSema versus placebo, as an adjunct to lifestyle intervention in 1,206 adults with type 2 diabetes and either obesity (BMI 30 kg/m2) or overweight (BMI 27 kg/m2)
Diabetes Obes Metab 2020
doi: 10.1186/s12974-022-02430-0
Discover personalized skincare solutions crafted to rejuvenate, restore, and enhance your natural beauty
US$ 24.73
US$ 24.64
US$ 29.83
US$ 21.45
US$ 26.33
